Company: Galectin Therapeutics
Job title: Chief Executive Officer & President
Harold Shlevin, Ph.D., has 25+ years of senior management experience in the development and commercialization of pharmaceuticals, diagnostics, and vaccines. Prior to his appointment as President and CEO of Galectin Therapeutics, he served as the company’s Chief Operating Officer and was responsible for all operational aspects of the company, including regulatory affairs & quality assurance, manufacturing, clinical development, business development, and commercial development.
Dr. Shlevin previously held leadership positions at Georgia Institute of Technology’s Advanced Technology Development Center (ATDC), Solvay Pharmaceuticals, CIBA Vision Ophthalmics where he was a co-founder, Tikvah Therapeutics, Altea Therapeutics and CIBA-Geigy Pharmaceuticals.
Dr. Shlevin earned a B.A. degree from Boston University and M.S. and Ph.D. degrees in physiology from the University of Rochester Medical School, as well as postdoctoral fellowship at Mayo Foundation and Mayo Medical School. He is currently a member of the Institute of Electrical and Electronics Engineers, Licensing Executives Society, American Physiological Society, American Society of Pharmacology and Experimental Therapeutics, and is an inventor on several issued and pending patents.